PUBLISHER: The Insight Partners | PRODUCT CODE: 1871426
PUBLISHER: The Insight Partners | PRODUCT CODE: 1871426
The microelectrode array in vitro market in the Middle East and Africa was valued at approximately US$ 0.53 million in 2023 and is projected to grow to US$ 0.72 million by 2031, reflecting a compound annual growth rate (CAGR) of 3.9% during this period.
Integration of Microelectrode Array Technologies with Organ-On-A-Chip
The advancement of organ-on-a-chip systems, which mimic the physiological conditions of human organs through microfluidics and engineered tissues, is significantly enhancing the microelectrode array in vitro market. When microelectrode array technology is integrated with these organ-on-a-chip systems, it allows for real-time monitoring of electrical activity, providing valuable insights into the functional responses of organ models. For example, a heart-on-a-chip that incorporates a microelectrode array can yield critical data on cardiac electrophysiology, enabling researchers to assess how various compounds affect heart rhythm and contractility. This capability is vital for understanding drug-induced cardiotoxicity, a major concern in pharmaceutical development.
A notable collaboration occurred in September 2022, when NETRI, a neuro-organs-on-chip start-up, partnered with Axion BioSystems to develop microfluidic devices equipped with high-throughput microelectrode arrays. This innovative technology enables neuroscientists to noninvasively measure the electrical activity of neural cells within complex in vitro models, thereby accelerating therapeutic discovery. The microelectrode array plays a central role in this organ-on-chip research, which aims to enhance biological models while minimizing animal testing. The focus areas include brain-on-a-chip technology for investigating neurodegenerative diseases, heart-on-a-chip technology, and blood-brain barrier modeling. Consequently, the integration of microelectrode array technologies with organ-on-a-chip devices is anticipated to drive new trends and growth in the market in the coming years.
Overview of the Middle East & Africa Microelectrode Array In Vitro Market
The microelectrode array in vitro market in the Middle East and Africa is segmented into key regions, including Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa. Factors such as rapid technological advancements in neuroscience and biomedical research, the presence of key industry players, and government initiatives aimed at enhancing healthcare and research infrastructure are expected to propel market growth in the region during the forecast period.
In South Africa, the healthcare sector is undergoing reforms to address challenges like high rates of HIV/AIDS, tuberculosis, and noncommunicable diseases such as cancer and diabetes. The National Health Insurance (NHI) initiative emphasizes the importance of biotechnology and medical device innovation, including the application of microelectrode arrays in research and diagnostics. The Department of Science and Technology (DST) and the South African Medical Research Council (SAMRC) are actively working to boost local production of biotechnology and medical devices, focusing on advanced tools for drug screening and disease modeling. Key market players such as NeuroNexus and Metrohm are contributing to the growth of the microelectrode array in vitro market in South Africa. The pharmaceutical sector in the country includes both local and international companies involved in drug discovery and development, with microelectrode arrays offering an efficient, high-throughput method for neurotoxicity screening, neuropharmacology studies, and testing drug efficacy on neural cells. The rising demand for effective drug testing platforms is driving the adoption of microelectrode arrays in South Africa.
Market Segmentation Analysis
The Middle East and Africa microelectrode array in vitro market is categorized by product, application, and country.
Key Companies in the Market
Prominent companies operating in the microelectrode array in vitro market include Tucker Davis Technologies, SCREEN Holdings Co., Ltd., Plexon Inc., MaxWell Biosystems AG, Harvard Bioscience Inc., Axion BioSystems Inc., 3Brain AG, NeuroNexus Technologies Inc., MicroElectrodeDevices, Blackrock Microsystems, Inc., NMI Technologietransfer GmbH, and BMSEED. These companies are at the forefront of innovation and development in the microelectrode array technology space.